Top Markets
#1 Seeker Seeker +146.01%
#2 MowCat MowCat +109.02%
#3 AI XOVIA AI XOVIA +103.40%
#4 Helium Helium +97.25%
#5 Pons Pons +43.39%
#6 UnifAI Network UnifAI Network +33.44%
#7 Zora Zora +30.95%
#8 Bounce Bounce +22.78%
#9 Zylo Ecosystem Zylo Ecosystem +22.03%
#10 pipedog pipedog +15.70%
Coin of the day
Seeker Seeker
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nxera Pharma Co., Ltd. Nxera Pharma Co., Ltd.

Nxera Pharma Co., Ltd.

4565
Classifica tra le azioni #11675
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a... Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
Prezzo delle azioni
$7.32
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$671.50M
Variazione (1 giorno)
1.08%
Variazione (1 anno)
16.38%
Paese
JP
Scambia Nxera Pharma Co., Ltd. (4565)

Categoria

Healthcare
Storico dividendi per Nxera Pharma Co., Ltd. (4565)
Nxera Pharma Co., Ltd. (simbolo azionario: 4565) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Nxera Pharma Co., Ltd. (4565) dal 2026 al 2026
Pagamenti annuali dei dividendi
Anno Dividendo (rettificato per split azionari) Cambia
Non abbastanza dati per le date fornite.
Elenco di tutti i pagamenti di dividendi
Anno Dividendo Cambia
Non abbastanza dati per le date fornite.
Dividendi di aziende simili o concorrenti
Azienda Numero di pagamenti di dividendi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH